{"nct_id":"NCT02475213","title":"Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer","status":"COMPLETED","status_verified_date":"2025-08","start_date":"2015-07","start_date_type":"ACTUAL","primary_completion_date":"2021-08-18","primary_completion_date_type":"ACTUAL","completion_date":"2021-08-18","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["MGNX"]}